Regimens for treating HIV infections and aids
AssigneesViiV Healthcare Company, Janssen Sciences Ireland Unlimited Company
InventorsHerta Crauwels, David Margolis, William R. Spreen, Andrew Spaltenstein, Peter Williams
Life of this patent
Estimating the term…
Abstract
A method of treating HIV comprising intramuscular administration once every 4 weeks or less frequently of a combination of cabotegravir or a pharmaceutically acceptable salt thereof and rilpivirine or a pharmaceutically acceptable salt thereof, including the option of discontinuing administration of a first oral anti-retroviral regimen and intramuscularly administering, once four weeks or less often said combination of cabotegravir and rilpivirine.
Claims30
A method of treating HIV-1 infection in a subject in need thereof, comprising intramuscularly administering into a gluteus medius muscle of the subject effective amounts of cabotegravir and rilpivirine resulting in the subject having a viral load of less than or equal to 50 copies of HIV-1 virus particles per mL of blood plasma (≤50 c/mL) in the subject after at least 96 weeks of administration,
- wherein the effective amounts of cabotegravir and rilpivirine result in the subject having the viral load of ≤50 c/mL and comprise 400 mg of cabotegravir in a 2-mL injectable formulation and 600 mg of rilpivirine in a separate 2-mL injectable formulation administered once every four weeks or once a month.
A method of treating HIV-1 infection in a subject in need thereof, comprising intramuscularly administering into a gluteus medius muscle of the subject effective amounts of cabotegravir and rilpivirine resulting in the subject having a viral load of less than or equal to 50 copies of HIV-1 virus particles per mL of blood plasma (≤50 c/mL) in the subject after at least 96 weeks of administration,
- wherein the effective amounts of cabotegravir and rilpivirine result in the subject having the viral load of ≤50 c/mL and comprise 600 mg of cabotegravir in a 3-mL injectable formulation and 900 mg of rilpivirine in a separate 3-mL injectable formulation administered every once eight weeks or once every two months.
A method of treating HIV-1 infection in a subject in need thereof, comprising intramuscularly administering into a gluteus medius muscle of the subject effective amounts of cabotegravir and rilpivirine which do not result in an emergent resistance-associated mutation in an HIV virus in the subject after at least 96 weeks of administration,
- wherein the effective amounts of cabotegravir and rilpivirine comprise 400 mg of cabotegravir in a 2-mL injectable formulation and 600 mg of rilpivirine in a separate 2-mL injectable formulation administered every four weeks or once a month.
A method of treating HIV-1 infection in a subject in need thereof, comprising intramuscularly administering into a gluteus medius muscle of the subject effective amounts of cabotegravir and rilpivirine which do not result in an emergent resistance-associated mutation in an HIV virus in the subject after at least 96 weeks of administration,
- wherein the effective amounts of cabotegravir and rilpivirine comprise 600 mg of cabotegravir in a 3-mL injectable formulation and 900 mg of rilpivirine in a separate 3-mL injectable formulation administered once every eight weeks or once every two months.
Dependencies are inferred from the claim text.